Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio’s lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). Inovio Pharmaceuticals Inc (NYSEMKT:INO) weekly performance is 25.93%. On last trading day company shares ended up $10.78. Analysts mean target price for the company is $19.20. Inovio Pharmaceuticals Inc (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is 6.19%.
Newmont Mining Corp (NYSE:NEM) declared force majeure on copper sales from Indonesia, after the nation’s ban on mineral ore exports forced it to shut down its mine in the country. Newmont, the world’s second-largest gold producer, is putting about 80 percent of its Batu Hijau mine employees on leave at reduced pay from June 6, it said in an e-mailed statement. Newmont halted output and copper concentrate processing at the facility on Sumbawa island on June 3.Newmont Mining Corp (NYSE:NEM) shares fell -1.90% in last trading session and ended the day on $22.67. Gross Margin is 33.90% and its return on assets is -10.40%. Newmont Mining Corp (NYSE:NEM) quarterly performance is -6.17%.
On June 5, 2014, Kandi Technologies Group, Inc. (NASDAQ:KNDI) celebrated the establishment of the nation’s first pure EV pilot community at the Kandi pure EV (Electric Vehicle) launching ceremony held at Zhuantang Xiangshan International Plaza in the Lake District of Hangzhou. To date, more than 700 Zhuantang district residents have registered for the EV long-term group leasing program. Kandi Technologies Group Inc (NASDAQ:KNDI) shares moved up 2.23% in last trading session and was closed at $12.36, while trading in range of $12.00 – $12.70. Kandi Technologies Group Inc (NASDAQ:KNDI) year to date (YTD) performance is 4.83%.
Certain subsidiaries of Pacific Ethanol, Inc. (NASDAQ:PEIX) are parties to that certain Second Amended and Restated Credit Agreement, dated as of October 29, 2012 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) that provides for a revolving credit facility of up to $35.0 million, Tranche A-1 term loans of $39.4 million, and Tranche A-2 term loans of $26.3 million. An aggregate of $31.7 million of the Tranche A-1 term loans are subject to a prepayment premium in the event any of these loans are repaid prior to maturity. Pacific Ethanol Inc (NASDAQ:PEIX) ended the last trading day at $14.14. Company weekly volatility is calculated as 4.25% and price to cash ratio as 36.51. Pacific Ethanol Inc (NASDAQ:PEIX) showed a positive weekly performance of 5.84%.
Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) announced that COMPASS, its Phase IIIb clinical trial comparing the efficacy and safety of the investigational product AVP-825 22mg to sumatriptan 100mg tablets for the treatment of acute migraines in adults, met the primary efficacy endpoint. AVP-825 is an investigational drug-device combination product consisting of low-dose sumatriptan powder delivered intranasally utilizing a novel Breath Powered™ delivery technology. In March 2014, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) of AVP-825 and the Prescription Drug User Fee Act (PDUFA) V goal date is November 26, 2014. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) net profit margin is -74.00% and weekly performance is 5.95%. On last trading day company shares ended up $5.34. Analysts mean target price for the company is $9.29. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) distance from 50-day simple moving average (SMA50) is 25.29%.